Lehavim, Israel

Efrat Manoff

This inventor holds 1 USPTO granted patent. Top assignee: Chemagis Ltd.. Active years: 2008.


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Efrat Manoff: Innovator in Letrozole Purification

Introduction

Efrat Manoff is a notable inventor based in Lehavim, Israel. He has made significant contributions to the field of pharmaceuticals, particularly in the purification processes of important compounds. His work has implications for the production of letrozole, a medication used in the treatment of breast cancer.

Latest Patents

Efrat Manoff holds a patent for a process titled "Letrozole purification process." This innovative method involves purifying a letrozole product that contains an isoletrozole impurity. The process includes converting a portion of the isoletrozole impurity into 4,4'-dicyanobenzophenone and subsequently removing this compound to yield a purified letrozole product. This advancement is crucial for enhancing the quality and efficacy of letrozole in medical applications.

Career Highlights

Efrat Manoff is associated with Chemagis Ltd., where he applies his expertise in pharmaceutical development. His work at Chemagis Ltd. has positioned him as a key player in the field of drug purification and formulation. With a focus on innovative solutions, he continues to contribute to advancements in pharmaceutical sciences.

Collaborations

Efrat collaborates with talented individuals such as Michal Hasson and Hila Isenberg. Their teamwork fosters a creative environment that drives innovation and enhances the development of new pharmaceutical processes.

Conclusion

Efrat Manoff's contributions to the purification of letrozole highlight his role as an important inventor in the pharmaceutical industry. His innovative processes not only improve product quality but also support advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…